MBX Biosciences, Inc. (MBX)
NMS – Real Time Price. Currency in USD
67.16
+1.15 (1.74%)
Market open: Aug 12, 2026, 10:01 AM EDT
66.01
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Find any stock by ticker or company name

NMS – Real Time Price. Currency in USD
67.16
+1.15 (1.74%)
Market open: Aug 12, 2026, 10:01 AM EDT
66.01
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $54.1M significantly exceed its total debt $3.3M, ensuring strong financial flexibility
Total current assets $427.9M exceed Total current liabilities $23.7M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$23.5M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 18.08 | 6.05 | 10 | |
| Quick ratio | 18.08 | 5.63 | 10 | |
| Debt to Equity | 0.01 | 0.30 | 10 | |
| Debt to Assets | 0.01 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -56K | -157K | -244K | -248K | -303K |
| Operating Income | -25M | -35M | -68M | -98M | -118M |
| Net Income | -26M | -33M | -62M | -87M | -104M |
| EBITDA | -25M | -35M | -68M | -98M | -118M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | -29.45 | 1.0 |
| Next quarter | N/A | -88.39 | 1.0 |
| Current year | N/A | -26.15 | 1.0 |
| Next year | N/A | -29.99 | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -57.73 | -52.93 | -13.93 | 3.3 |
| Y/Y | 999 | -91.09 | -34.47 | -29.66 | 3.3 |
| 3y average | 999 | -51.72 | N/A | -52.2 | 3.3 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 2.7 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |